Use of aromatase inhibitors in children and adolescents with disorders of growth and adolescent development.
Although treatment of children and adolescents who have disorders of growth and adolescent development with aromatase inhibitors is increasingly common, data for or against their use are extremely limited. Precocious puberty, short stature, and gynecomastia are conditions for which inhibition of the enzyme aromatase might prove beneficial to reduce clinical signs of estrogenization and/or estrogen-mediated skeletal maturation. In this report, we summarize the published data regarding the use of aromatase inhibitors in these conditions, and review known and potential benefits, safety concerns, and shortcomings of the available information.
Shulman
Dorothy I
DI
All Children's Hospital, St Petersburg, Florida 33701, USA. dshulman@health.usf.edu
Francis
Gary L
GL
Palmert
Mark R
MR
Eugster
Erica A
EA
D000293:Adolescent; D000367:Age Factors; D047072:Aromatase Inhibitors / Q000627:therapeutic use*; D001827:Body Height / Q000187:drug effects; D015519:Bone Density / Q000187:drug effects; D001846:Bone Development / Q000187:drug effects / Q000502:physiology; D002648:Child; D002657:Child Development / Q000187:drug effects / Q000502:physiology; D002675:Child, Preschool; D005260:Female; D006130:Growth Disorders / Q000175:diagnosis / Q000188:drug therapy*; D006177:Gynecomastia / Q000188:drug therapy*; D006801:Humans; D008297:Male; D011379:Prognosis; D011629:Puberty, Precocious / Q000188:drug therapy*; D018570:Risk Assessment; D012680:Sensitivity and Specificity; D012737:Sex Factors; D012741:Sexual Maturation / Q000187:drug effects / Q000502:physiology
D047072:Aromatase Inhibitors